[2]Rost NS, et al. Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thro...
Screening for the presence of thrombus in the left atrial or left atrium appendage by transesophageal echocardiography (TEE) is an alternative to routine pre-anticoagulation in candidates for cardioversion of AF [ 1 ]. ACC/AHA/ESC guidelines recommend anticoagulation treatment of patients in whom no...
If anticoagulation is to be restarted in these patients, use of a direct oral anticoagulant might be preferable on the basis of the lower risk of cerebral bleeding versus warfarin in other contexts. Show abstract 2024 ESC Guidelines for the management of atrial fibrillation developed in ...
The cornerstones of atrial fibrillation (AF) management are rate control and anticoagulation [1, 20] and rhythm control for those symptomatically limited by AF. [20] The clinical decision to use a rhythm-control or rate-control strategy requires an integrated consideration of several factors, inclu...
Current guidelines make identical recommendations for anticoagulation regardless of AF pattern or burden; however, a review of recent evidence suggests that higher AF burden is associated with higher risk of stroke. It is unclear whether the risk increases continuously or whether a threshold exists; ...
The 2001 ACC/AHA/ESCAFguidelines recommend anticoagulation for patients considered at medium or high risk of thromboembolism. 2001年ACC/AHA/ESC房颤指南推荐对于中危或高危血栓栓塞的房颤患者进行抗凝治疗。 Among individuals with severe sepsis, new-onsetAFwas associated with increased adjusted risks of in-...
The antiarrhythmic drugs and anticoagulation regimens were maintained for 3 months postoperatively in all patients and then adapted according to the rhythm results. In patients without contraindications, amiodarone was used as first-line antiarrhythmic drug therapy; otherwise, other class I or III ...
NOAH–AFNET 6 will randomize 3,400 patients with AHRE, but without documented AF, aged ≥65 years with at least 1 other stroke risk factor, to oral anticoagulation therapy (edoxaban) or no anticoagulation. All patients will be followed until the end of this investigator-driven, prospective, ...
Of patients meeting the primary end point, 13 (10.2%) had 1 or more episodes lasting 24 hours or longer, and oral anticoagulation therapy was prescribed for 72 patients (56.3%). Conclusions and Relevance The incidence of previously undiagnosed AF may be substantial in patients with risk factors...
several studies had already been published that reported data that support the use of only one antiplatelet on top OAC in patients with AF who underwent recent PCI. The What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST) stud...